A method for the treatment of proliferative disorders and other pathological conditions mediated by BCR-ABL, c-KIT, DDR1, DDR2, or PDGF-R kinase activity
The present invention relates to a regimen for the administration of a pyrimidylaminobenzamide of formula I wherein the radicals as defined herein, or of a pharmaceutically acceptable salt thereof, for the treatment of proliferative disorders, particularly solid and liquid tumors, and other pathological conditions mediated by the Bcr-Abl oncoprotein, the cell transmembrane tyrosine kinase receptor c-Kit, DDR1 (discoidin domain receptor 1), DDR2 (discoidin domain receptor 2) or PDGF-R (platelet derived growth factor receptor) kinase activity, wherein the pyrimidylaminobenzamide of formula I and, optionally, pharmaceutically acceptable carriers, are dispersed in a fruit preparation.
